Difference between revisions of "Eltrombopag (Promacta)"
m |
m |
||
| Line 20: | Line 20: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | [[Category: | + | [[Category:Hematopoietic growth factors]] |
[[Category:Hemostasis medications]] | [[Category:Hemostasis medications]] | ||
[[Category:Megakaryocyte growth factors]] | [[Category:Megakaryocyte growth factors]] | ||
Revision as of 13:22, 18 June 2014
Also known as Revolade or SB-497115-GR.
General information
Class/mechanism: Thrombopoietin (TPO) receptor agonist; interacts with the transmembrane domain of the TPO-receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Idiopathic (immune) thrombocytopenic purpura (ITP)
Patient drug information
- Eltrombopag (Promacta) package insert pages 21-26[1]
- Brief patient counseling information can be found on pages 19-20 of the package insert[1]
- Eltrombopag (Promacta) patient drug information (UpToDate)[4]